Pluristem Therapeutics Inc. (PSTI)

1.36
NASDAQ : Health Technology
Prev Close 1.38
Day Low/High 1.36 / 1.39
52 Wk Low/High 1.06 / 2.12
Avg Volume 269.50K
Exchange NASDAQ
Shares Outstanding 110.10M
Market Cap 147.53M
EPS -0.30
P/E Ratio 4.18
Div & Yield N.A. (N.A)

Latest News

Peer-Reviewed Article Published On Pluristem's PLX-PAD Cells' Mechanism Of Action To Restore Blood Flow In Ischemic Tissue

Peer-Reviewed Article Published On Pluristem's PLX-PAD Cells' Mechanism Of Action To Restore Blood Flow In Ischemic Tissue

Data supports advanced PLX-PAD clinical studies including dosing regimen, systemic therapeutic effects and superiority of the cells over cytokines

Pluristem Expands Its Reach In The Treatment Of Impaired Hematopoietic Systems With A European Patent Covering PLX-R18 In Chemotherapy, ARS, Genetic Disorders And Autoimmune Diseases

Pluristem Expands Its Reach In The Treatment Of Impaired Hematopoietic Systems With A European Patent Covering PLX-R18 In Chemotherapy, ARS, Genetic Disorders And Autoimmune Diseases

Patent significantly expands potential indications for PLX-R18 and grants Pluristem broad coverage in the treatment of damaged hematopoietic systems

FDA Grants Pluristem Orphan Drug Designation For Its PLX-R18 Cell Therapy As Treatment For Acute Radiation Syndrome

FDA Grants Pluristem Orphan Drug Designation For Its PLX-R18 Cell Therapy As Treatment For Acute Radiation Syndrome

Pluristem's ARS program is developed and funded by the U.S. National Institutes of Health and the U.S. Department of Defense, and is in preparation for a pivotal study

Biotech Movers: Disappointment for Bristol-Myers Kidney Combo Boosts Exelixis

Biotech Movers: Disappointment for Bristol-Myers Kidney Combo Boosts Exelixis

Previously studies already showed improvement from use of Exelixis's Cabometyx over Pfizer's Sutent in treating kidney cancer patients.

First Week of December 15th Options Trading For Pluristem Therapeutics (PSTI)

Investors in Pluristem Therapeutics Inc saw new options begin trading this week, for the December 15th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 225 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.